Loading...
ESMO congress Lung Cancer 20232025-01-28T17:10:39+01:00

ESMO 2023 Lung Cancer – hybrid, Madrid

 

Lecture Board: Maximilian Hochmair, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2023 – lung cancer

ESMO 2023 Lung Cancer

Full report

ESMO Lung Cancer 2023 EXPERT INTERVIEWS

James R. M. Black provides an overview of the potential of ctDNA in pre-operative disease stratification for early lung cancer by highlighting data from an ultra-sensitive and specific ctDNA approach. Considering the challenges of comprehensive tissue sampling and that subclones may evade tumor biopsy detection due to undersampling of metastatic sites at relapse, he finally discusses what insights ctDNA-based methods could provide into the process of metastasis spread.

Sebastian Kobold discusses the growing interest in using CAR-T cell therapy as an innovative approach to treat solid tumors in the future, as well as T cell receptor T cell therapy. Although there are still some hurdles to overcome, he discusses what remarkable developments can be expected in this field in the coming years.

Gerrina Ruiter explains the limitations of previous HER2 agents tested in solid tumors while highlighting the encouraging preliminary results of the BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors. Lastly, she talks about the challenges of bispecific antibodies, which have recently shown robust efficacy in solid tumors.

Åslaug Helland summarizes the results from the NIPU trial combining UV1 vaccination and immunotherapy in the setting of malignant mesothelioma. Furthermore, she explains how study designs might be modified to expand treatment options in personalized medicine and explains which data could potentially be used as external comparator arms where randomized controlled trials might be unethical, or no defined standard treatment and/or too small patient groups are available.

David C. Currow highlights the encouraging results of two Phase 3 randomized trials that investigated a ghrelin antagonist to combat cachexia in NSCLC patients. He also provides an overview of the recent advancements in integrating palliative care for cancer patients, and addresses the ongoing challenges that we still face in terms of end-of-life care in everyday practice.

Go to Top